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Abstract
In a widely accepted model, the steroid receptor RNA activator protein (SRA protein; SRAP) modulates the
transcriptional regulatory activity of SRA RNA by binding a specific stem–loop of SRA. We first confirmed
that SRAP is present in the nucleus as well as the cytoplasm of MCF-7 breast cancer cells, where it is
expressed at the level of about 105 molecules per cell. However, our SRAP–RNA binding experiments, both
in vitro with recombinant protein and in cultured cells with plasmid-expressed protein and RNA, did not
reveal a specific interaction between SRAP and SRA. We determined the crystal structure of the carboxy-
terminal domain of human SRAP and found that it does not have the postulated RRM (RNA recognition
motif). The structure is a five-helix bundle that is distinct from known RNA-binding motifs and instead is
similar to the carboxy-terminal domain of the yeast spliceosome protein PRP18, which stabilizes specific
protein–protein interactions within a multisubunit mRNA splicing complex. SRA binding experiments with
this domain gave negative results. Transcriptional regulation by SRA/SRAP was examined with siRNA
knockdown. Effects on both specific estrogen-responsive genes and genes identified by RNA-seq as
candidates for regulation were examined in MCF-7 cells. Only a small effect (~20% change) on one gene
resulting from depletion of SRA/SRAP could be confirmed. We conclude that the current model for SRAP
function must be reevaluated; we suggest that SRAP may function in a different context to stabilize specific
intermolecular interactions in the nucleus.
© 2014 Elsevier Ltd. All rights reserved.
Introduction
Steroid hormone receptors bind hormones such
as estrogen, glucocorticoid, or progesterone within
the cell and then regulate transcription of steroid-
responsive genes. In 1999, an RNA that increased
the transcriptional activation of steroid receptors
was identified using a yeast two-hybrid screen with
the amino-terminal domain of the human progester-
one receptor as bait [1]. Hence, the RNA was
entitled “steroid receptor RNA activator”, or “SRA”. It
was subsequently proposed that SRA asserts
similar regulatory effects on transcription in addi-
tional biological contexts, such as myogenesis [2]
and adipogenesis [3], reviewed recently byColley and
Leedman [4].
Multiple splice variants of SRA gene transcripts
have been identified, in addition to the three that
were originally described [5,6]. Some of them include
a candidate open reading frame and two potential
start codons for a protein of 224 or 236 amino acids.
Translation of this protein from coding variants has
been confirmed [7–9], and the protein has been
designated “steroid receptor RNA activator protein”,
or “SRAP”. The properties of SRAP, including its
evolutionary conservation and tissue distribution, as
0022-2836/$ - see front matter © 2014 Elsevier Ltd. All rights reserved. J. Mol. Biol. (2014) 426, 1766–1785
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well as its proposed biological activity as a modulator
of SRA-dependent transcriptional regulation, have
been reviewed [10].
Both SRA RNA and SRAP have been suggested to
regulate the transcriptional activity of estrogen recep-
tor (ER) [11–15]. The ratio between the noncoding and
coding forms of SRA has been suggested to correlate
with the invasion of breast cancer cells [16]. A model
for intertwined activities of SRA and SRAP has
emerged in which (i) SRA RNA participates as a
co-regulator (inmost cases reported, a co-activator) of
transcription of target genes; (ii) SRAP modulates the
activity of SRA by binding a specific stem–loop,
designated “stem–loop 7” (STL7), of the RNA; and (iii)
the level of SRAP, and by implication the level of its
modulation, is controlled by the ratio of coding to
noncoding splice variants of theSRAgene transcripts.
In essence, this model suggests an intriguing feed-
backmechanismbywhich the activity of a “sometimes
coding” RNA is self-regulated by the level of modu-
lating protein produced by coding variants of its
transcripts. Additionally, other proteins have been
suggested to modulate SRA transcriptional regula-
tion, including the SMRT/HDAC1-associated repres-
sor protein (SHARP) [17] and the SRA stem–loop
interacting RNA binding protein (SLIRP) [18].
To delineate the molecular basis for this proposed
regulatory mechanism, we undertook biochemical,
structural, genetic, and cell biology studies. To this
end, we have expressed and purified recombinant
SRAP variants and have carried out protein–RNA
binding assays with SRA derivatives. Additionally,
we tested in vivo RNA pull-down with SRAP and
have searched for evidence of SRA/SRAP-depen-
dent regulation of transcription of specific genes
through siRNA knockdown experiments in cells. Our
results generally do not corroborate the current
model for SRA/SRAP interaction and regulation.
Results
Expression level and cellular localization of SRAP
in MCF-7 cells
An essential requirement for SRAP to assert an
activity as a regulator of transcription is that the
protein is expressed and targeted to the cell nucleus.
In this context, we measured the expression level
and cellular localization of SRAP in the human
breast ductal carcinoma cell line, MCF-7. To
determine the endogenous expression level of
SRAP, we used Western blotting, comparing the
signal from cell lysates to that of purified recombi-
nant SRAP as a standard (Fig. 1a). (The mobility of
endogenous SRAP in MCF-7 on SDS-PAGE differs
from that of recombinant SRAP. As discussed in
more detail in Materials and Methods and Fig. S1,
the MCF-7 SRAP isoform has a V → RL insertion
and may in addition be posttranslationally modified.
The epitope of the antibody used in the Western blot
lies outside the site of the mutation.) Quantification of
the Western signal demonstrated that there are
approximately 1.8 × 105 molecules of SRAP per
MCF-7 cell.
Previous studies of SRAP expressed from a
plasmid transfected into MCF-7 cells [8] and
endogenous SRAP in HeLa cells [19] suggest that
it localizes to both the nucleus and cytoplasm. To
examine the localization of endogenous SRAP in
MCF-7 cells, we performed immunofluorescence
experiments (Fig. 1b). We used two different rabbit
polyclonal antibodies (Abcam ab72407 and
ab72552) independently to check for consistency
of results (upper and lower panels, Fig. 1b). We
observed both nuclear and cytoplasmic localization
of SRAP (top rows of figure). The signal was
substantially attenuated when SRAP was knocked
down with a siRNA pool (pool 2 SRA siRNA,
described in more detail below) (middle rows). It was
also attenuated when recombinant SRAP protein was
added as a competitive inhibitor of antibody binding
(bottom rows). While this article was in preparation,
another group published results on the localization of
endogenous SRAP in MCF-7 cells, using different
antibodies [20]; our results are in agreement with
theirs.
In summary, SRAP is expressed at substantial
levels (on the order of 105 molecules per cell) in
MCF-7 cells. In agreement with the results of others,
we find SRAP in both the cytoplasm and the nucleus,
supporting the possibility that it asserts a biochem-
ical activity in the nucleus.
Binding of SRARNA to recombinant SRAP in vitro
It has been proposed that SRAP modulates
transcriptional regulation by SRA RNA by binding a
specific putative stem–loop of the RNA, designated
STL7 in the literature [6]. Therefore, we first attempted
to demonstrate a specific SRAP–RNA interaction
in vitro with purified components. Recombinant
SRAP proteins initiating from both the first start
codon [designated SRAP (1–236) for the amino
acids it encompasses] and the second start codon
[SRAP (13–236)] were expressed in Escherichia coli
as carboxy-terminal fusions tomaltose binding protein
(MBP) and purified after protease cleavage of the
MBP tag as described in Materials and Methods. Our
data (Fig. S1 and discussed in Materials and
Methods) show that the second start codon is used
predominantly in vivo; hence, SRAP (13–236)was the
primary form used for in vitro experiments, with the
primary conclusions being corroborated with experi-
ments using SRAP (1–236).
For electrophoretic mobility shift assays (EMSAs),
RNAs were synthesized by in vitro transcription,
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Fig. 1. SRAPexpression level and localization inMCF-7 cells. (a) SRAP quantitativeWestern blot. Left: lanes 1–6, purified
SRAP (13–236) protein; lane 7, lysate from ~120,000 MCF-7 cells. SRAP was probed with Abcam antibody ab72552. Right:
plot ofWestern signal versus amount of SRAP. Open circle, signal from cell lysate. (b) Immunofluorescence analysis of SRAP
in MCF-7 cells. SRAP was probed with Abcam antibodies ab72407 (top panels) or ab72552 (bottom panels). The signal
specificity was confirmed by knocking down SRAP with pool 2 SRA siRNA (middle rows) as well as by competition with
recombinant SRAP (13–236) protein (bottom rows).
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purified, and labeled as described in Materials and
Methods. Initial efforts to demonstrate binding of
SRAP to STL7 of SRA RNA (Fig. 2a), which has
been proposed to be its specific target [6], failed to
yield positive results. Hence, a control binding
experiment was implemented with the protein
SLIRP, which was originally isolated and character-
ized as a protein that binds STL7 [18]. Using a
recombinant MBP–SLIRP fusion that was expressed
and purified from E. coli, we demonstrated that under
the conditions of our experiments, SLIRP binds
STL7 with an apparent affinity in the micromolar
range (Fig. 2b). Using the same conditions, SRAP
showed no apparent binding of STL7 at a concen-
tration of 16 μM (Fig. 2c).
We next attempted binding experiments with a
938-nucleotide construct of SRA RNA, which we
refer to as “full length”, and large fragments thereof
(Fig. 2d). Throughout transcription and purification,
denaturation of these RNAs was avoided. Loading
dyes were excluded from samples that had both
protein and RNA to preclude the possibility of dye
interference with SRA–SRAP interaction. Binding
to full-length SRA RNA was also checked with SRAP
(1–236), the longer putative translation product;
no substantial differences from results with SRAP
(13–236) were found. These experiments demon-
strate a very weak affinity of SRAP for SRA RNA, in
the micromolar range. They also show that SRAP
binds large, non-overlapping fragments of SRA RNA
(fragments I + II, I, II, and III) with similar affinities,
suggesting a sequence- and site-nonspecific RNA
binding activity.
Binding of SRA RNA to SRAP in cultured
HEK293T cells
Arguably, a failure to demonstrate a specific
interaction between SRAP and SRA RNA in vitro
might be due to any of a number of deficiencies in the
purified system, such as lack of posttranscriptional
modification of the RNA [21], lack of posttranslational
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Fig. 2. Direct assay for SRA RNA binding by SRAP in vitro. (a) Schematic diagram of RNA fragments used for EMSA.
Numbering corresponds to NCBI reference sequence NM_001035235. (b) Control gel shift of STL-7 RNA by MBP–SLIRP.
(c) Gel shift of STL-7 RNA by SRAP. (d) Gel shift of full-length SRA RNA and subfragments thereof by SRAP.
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modification of the protein [22–24], absence of other
essential binding partners in a multi-component
complex, and lack of assembly chaperones. To
address this concern, we coexpressed SRAP and
SRA RNA in HEK293T cells in order to include
intracellular factors and/or modifications that might
be essential for complex formation. In parallel, we
carried out experiments with intracellular expression
of human telomerase reverse transcriptase (hTERT)
and human telomerase RNA (hTR), a system for
which successful coexpression and assembly of
components into an active protein–RNA complex
are well documented (Ref. [25] and references
therein).
Mimicking the hTERT/hTR precedent, the pro-
tein-coding sequence of hTERT was replaced with
that of SRAP in a mammalian expression plasmid
that utilizes an amino-terminal 3×FLAG tag, and the
coding sequence of hTR was replaced with that of
SRA RNA, with the modification that the two ATG
translational start codons were mutated to TAG in
order to preclude expression of SRAP from this
plasmid, an approach for which there is a precedent
[26].
After co-transfection and growth with the alternative
protein–RNAplasmid combinations, 3×FLAG-tagged
protein (SRAP or hTERT) was adsorbed to anti-FLAG
beads. RNA was isolated from both the beads
(pull-down) and the residual supernatant from the
pull-down. Samples were run on denaturing gels and
RNAwas detectedwithNorthern blots (Fig. 3). In each
of three replicate experiments, SRAP failed to pull
down any SRA RNA (Fig. 3a). hTERT successfully
pulled down themajority of the hTRRNA, while SRAP
did not pull down hTR (Fig. 3b). Western blots
demonstrated that SRAPwas expressed at significant
levels in the HEK293T cells under the conditions of
our experiments and that anti-FLAG beads success-
fully bound it for pull-down (Fig. 3c). Anti-FLAG
Western blots on samples with equal amounts of
SRAP or hTERT material (lysate or pull-down) run on
the same gel provided a direct comparison of relative
expression levels of the two proteins; SRAP was
expressed at substantially higher levels than hTERT
in our experiments (Fig. 3d).
In summary, in these experiments, we find no
evidence for formation of a stable complex that
includes SRAP and SRA RNA in cultured human
cells.
Structure and activity of the carboxy-terminal
domain of SRAP
It has been noted that the sequence of residues
L163LVQEL of SRAP is consistent with an “RNP-2”
RNA binding motif found in some RNA recognition
motif (RRM) structural domains [27], leading to the
suggestion that the carboxy-terminal domain of
SRAP is an RNA binding motif [5]. In support of
this suggestion, it was shown that mutating the
hexapeptide motif to GGGQEL (mutated residues
underlined) impaired SRAP-dependent pull down of
SRA RNA in HEK293 cells. To examine this
suggestion, we pursued structural and biochemical
studies on this domain.
A fragment of human SRAP consisting of residues
105–215, with an amino-terminal V105M mutation,
was crystallized. The structure was solved to 2.8 Å
resolution by molecular replacement, using an
unpublished NMR model of the mouse homolog
[Protein Data Bank (PDB) ID: 2YRU, 85% identical in
sequence], as described in Materials and Methods.
Correct register of the sequence placement was
confirmed by the overlap of sulfur atoms of cysteine
and methionine residues of the model with peaks of
an anomalous difference Fourier computed using
anomalous differences derived from data collected
at λ = 1.5 Å (Fig. S2). There are two SRAP fragment
protomers per asymmetric unit. They were modeled
and refined independently; they superimpose with a
root-mean-square deviation (rmsd) of distances
between Cα carbons of 0.4 Å. The protomers of
the refined structure superimpose on the NMR
model used in molecular replacement with an rmsd
difference between Cα carbons of 0.8 Å.
The structure does not comprise an RRM, but
rather a five-helix bundle (Fig. 4). The five-helix
bundle was noted previously for the NMR structure,
although the absence of an RRM was not discussed
[10]. For discussion, the helices are designated A–E
sequentially. The hexapeptide suggested to be an
RNA binding motif lies within helix C (Fig. 4a and b).
Of the three residues that were mutated to glycine,
the side chains of two of them, Leu165 and Val166,
are packed in the hydrophobic interior of the protein.
Therefore, mutation of these residues would be
expected to disrupt the folding of the protein.
EMSA experiments were performed to test wheth-
er the carboxy-terminal domain of SRAP binds SRA
RNA fragments. Under experimental conditions in
which full-length SRAP weakly bound SRA and large
subfragments thereof, the fragment SRAP
(V105M-215) failed to manifest any binding of SRA
RNA fragment I, II, or III at 10 μMprotein concentration
(Fig. S3).
A search for similar protein structures was
undertaken with the DALI server.† A single structure,
a carboxy-terminal domain of yeast splicing factor
PRP18, was found; 99 amino acid residues of the
PRP18 domain aligned with the SRAP domain with
an rmsd of Cα positions of 2.0 Å and sequence
identity of 16% between aligned residues. This
similarity has been noted previously [10]. The
relationship of the PRP18 domain to that of SRAP
and the relationship of each to its respective parent
protein are summarized in Fig. 4c. The structural
similarity is shown in Fig. 4d. Both domains are
five-helix bundles; the most significant difference
1770 SRAP Structure and Function
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between them is an insertion between helices D and
E of PRP18, much of which was disordered in that
crystal structure.
It is somewhat surprising that only a single
structural homolog to the SRAP five-helix bundle
was found, in view of the simplicity of the structure. In
this context, we can ask what is unique about this
particular fold. Arguably the most notable feature,
relative to other folds such as four-helix bundles, is
the manner in which helix D projects from a
“platform” formed by helices C and E. In Discussion,
we consider whether this may have functional
significance.
Effects of SRA knockdown on estrogen signaling
in MCF-7 cells
Lack of evidence from our experiments in vitro and
in cultured cells for a specific, stable complex
between SRAP and SRA RNA does not preclude
the possibility that SRAP or SRA modulates tran-
scription of specific target genes independent of the
other component. Since both SRA and SRAP were
suggested to perform regulatory roles in estrogen
signaling, we investigated SRA/SRAP modulation of
estrogen-dependent transcription in MCF-7 cells
(which have only ERα and are devoid of ERβ)
upon depletion of endogenous SRA/SRAP through
siRNA knockdown. For these experiments, we
utilized knockdowns rather than overexpression out
of concern that overexpression may drive interac-
tions that do not occur when the components are
present at physiological concentrations.
Our strategywas to use a pool of several siRNAs for
knockdown experiments rather than just a single
siRNA, since this has been shown to mitigate
off-target effects [28]. Initially, we compared the
efficacy of two siRNA reagent pools. The first (“pool
1”, Dharmacon Smartpool, D-120329) has been used
previously in expression profiling of the SRA gene
[29], while the second (“pool 2”, Thermo Scientific
ON-TARGETplus), which became available more
recently, is designed to further reduce off-target
effects by dual-strand modification [30]. A control set
of non-target siRNAs was designed for pool 1 by
scrambling the sequence of each siRNA; a control set
of non-target siRNAs was commercially available for
pool 2.
We observed a more complete knockdown of SRA
RNA with pool 2, to b10% of control levels, versus
pool 1, ~20% of control levels (Fig. 5a). Additionally,
we observed that MCF-7 cells transfected with pool 1
SRA siRNA exhibited a significantly slower growth
rate (p b 0.05) than cells in the absence of siRNA or
transfected with pool 1 control siRNA (Fig. 5b).
Following up on this observation, we transfected
MCF-7 cells with individual siRNAs of pool 1 SRA
siRNA and pool 1 control siRNA. Only one siRNA
induced the attenuation of cell growth (Fig. S4),
suggesting that this phenotype is an off-target effect.
This may correlate with the earlier observation that
several cell-growth-related genes showed expres-
sion level changes when SRA was knocked down
with pool 1 SRA siRNA [29]. We did not observe a
similar effect on cell growth rate with pool 2 SRA
siRNA. Consequently, we used pool 2 SRA siRNA
and control siRNA for subsequent experiments.
To optimize knockdown conditions, we examined
the time dependence of the siRNA treatment (Fig. 5c
and d). At all the time points we tested (1–3 days
after siRNA transfection), pool 2 SRA siRNA induced
efficient knockdown of both SRA RNA (Fig. 5c) and
SRAP protein (Fig. 5d), and the knockdown efficiency
was stable throughout the 3-day time course.
Additionally, to optimize estrogen-dependent gene
expression signals within the physiological range of
estrogen levels, various 17β-estradiol concentra-
tions were tested. Fulvestrant, an antagonist of ERs,
was used to confirm that the effects observed were
caused specifically by 17β-estradiol signaling
through ERs. The results (Fig. S5) show that pS2
(the Trefoil factor 1 gene) and PR (progesterone
receptor gene), two endogenousestrogen-responsive
genes, were clearly induced by 17β-estradiol treat-
mentwhen cells were grown in hormone-freemedia to
reduce the background expression level. The level of
SRA RNA, however, was not affected by 17β-estra-
diol. By assessing the gene expression levels of pS2
and PR in a 17β-estradiol dose response experiment
(lanes 8–11) compared to expression in unsupple-
mented medium (lane 3), we chose a 17β-estradiol
concentration of 0.1 nM, the lowest level that induces
Fig. 3. Testing for SRAP–SRA RNA binding in human cells by coimmunoprecipitation. Protein–RNA pairs were
expressed in HEK293T cells using a dual plasmid system as described in Materials and Methods. Anti-FLAG peptide
beads were used to pull down FLAG-tagged protein (SRAP or hTERT) from cell lysates. RNA (SRA or hTR) was trizol
extracted from lysate (LYS), pull-down beads (PD), and pull-down supernatant (SUPT). For each set of samples, volume of
SUPT used (corrected for dilution) and volume of PD (corrected for concentration by centrifugation and resuspension)
were approximately equal to volume of LYS used. Samples were run on a denaturing 4% acrylamide gel; ~2 ng each of
in vitro transcribed SRA and hTR RNAs were run in separate lanes for reference. (a) Northern blot probed with labeled
anti-SRA oligonucleotides. (b) Northern blot from (a) probed additionally with anti-hTR oligonucleotides. (c) Western blot with
an anti-FLAG antibody of cell lysate and pull-down samples from SRAP/SRA and SRAP/hTR expression, demonstrating
efficient pull-down of SRA protein. Volume of PD (corrected for concentration by centrifugation and resuspension) was
approximately equal to volume of LYS. (d)Western blot with an anti-FLAG antibody of cell lysate and pull-down samples from
SRAP/SRAand hTERT/hTR expression (equal volumes of each), demonstrating the expression level of SRAP relative to that
of TERT.
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Fig. 4. Crystal structure of SRAP carboxy-terminal domain and its similarity to the structure of PRP18 carboxy-terminal
domain. (a and b) Cartoon drawing of the crystallographic structure of the carboxy-terminal domain of SRAP (residues
105–215). (a) Side view; helices are lettered sequentially. Side chains of the six residues suggested to comprise an RNP-2
motif, L163LVQEL, shown as stick models [6]. The three residues that were mutated to glycines to test RNA binding in the
published study are additionally indicated with semitransparent spheres. (b) Top view. (c) Schematic drawing of the
domain organization of SRAP and PRP18, indicating the fragments that were crystallized. (d) Cartoon drawing of the
SRAP and PRP18 domains illustrating their similarity in structure. Molecular drawings were made with PyMOL (http://www.
pymol.org).
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a substantial increase in mRNA levels, for experi-
ments measuring the expression of endogenous
genes.
We then treated cells transfected with pool 2
control siRNA or pool 2 SRA siRNA with 0.1 nM
17β-estradiol and measured the endogenous mRNA
level of pS2, PR, and GREB1 (growth regulation by
estrogen in breast cancer 1), another estrogen-
responsive gene (Fig. 6a). To monitor both early and
late responses, we tested different 17β-estradiol
treatment times (7.5 h and 24.5 h). Single-replicate
measurements under each condition revealed a
clear and consistent trend. SRA RNA was efficiently
knocked down (top panels), and the three estro-
gen-responsive genes exhibited substantially in-
creased mRNA levels in response to 17β-estradiol
treatment (compare lane 6 to lanes 2–5). However,
depleting SRA had no apparent effect on the
responses of the pS2 and GREB1 genes to
17β-estradiol, while the PR RNA levels showed
~20% enhancement. We then monitored the mRNA
levels of pS2 and PR over a 3-day period after siRNA
transfection, making measurements in triplicate to
verify statistical significance, and found the same
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Fig. 5. Knockdown of SRA RNA and SRAP. In each case, approximately 200,000 MCF-7 cells were transfected with
25 nM of the indicated siRNA pool or no RNA. (a) SRA RNA level, measured by RT-qPCR (primer: SRA-3, with GAPDH
mRNA as internal control) 3 days after transfection (n = 1). (b) Cell number, measured 3 days after transfection by flow
cytometry (error bars represent SD, n = 2). (c and d) Time dependence of knockdown efficiency of pool 2. MCF-7 cells
were transfected with 25 nM corresponding siRNA pool. (c) SRA RNA level, measured by RT-qPCR (error bars represent
SD for n = 3; primer: SRA-4, with GAPDH mRNA as internal control). (d) SRAP protein level, measured by Western blot
(antibody: Abcam ab72552, with GAPDH protein as internal control).
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trend; PR showed ~20% increase in mRNA level after
SRA knockdown, while pS2 showed no significant
change (Fig. S6).
It has previously been reported that overexpression
of SRA RNA in HeLa cells from a human cytomega-
lovirus-driven expression vector enhances the lucifer-
ase signal from a hormone-responsive luciferase
reporter plasmid approximately 10-fold over its level
in the absence of SRA [1,31]. To look for similar
behavior in MCF-7 cells, we used two different
plasmids with the firefly luciferase gene under
the control of estrogen-responsive promoters:
pGL3-3 × ERE-Luc, which has three copies of
the classic vitellogenin ERE (estrogen-responsive
element), and pGL3-vitellogenin A2-Luc, which has
the endogenous vitellogeninA2 promoter sequence−
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Fig. 6. Effect of SRA RNA knockdown on estrogen-dependent gene expression. (a) Knocking down SRA does not
significantly affect the transcription of estrogen-dependent genes pS2, PR, and GREB1 in MCF-7 cells. Lane 1, MCF-7
cells were grown in complete medium and transfected with 25 nM corresponding siRNA pool; lanes 2–6, MCF-7 cells were
grown in hormone-free medium for 3 days and then transfected with 25 nM corresponding siRNA pool. Twenty-four hours
after transfection, the cells were treated with 17β-estradiol with or without fulvestrant for 7.5 h (left panels) or 24.5 h (right
panels). The RNA level of SRA, pS2, PR, and GREB1 was quantified with RT-qPCR with GAPDH mRNA as an internal
control (SRA primer: SRA-4) (n = 1). (b) Knocking down SRA does not significantly affect the transcription of an
estrogen-controlled luciferase gene from transfected plasmids. MCF-7 cells were grown in hormone-free medium for
3 days and then transfected with 25 nM corresponding siRNA pool. Twenty-three hours after siRNA transfection, the cells
were transfected with luciferase reporter plasmids. Five hours after the plasmid transfection, cells were treated with 10 nM
17β-estradiol or ethanol vehicle. Eighteen hours after that, cells were harvested and luciferase activity was measured
(error bars represent SD, n = 3).
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331 to −87.We askedwhether depletion of SRARNA
from endogenous levels would result in a reduction of
estrogen-dependent luciferase signal in MCF-7 cells.
In experiments with these plasmids, we treated
MCF-7 cells with a higher level of 17β-estradiol (10
nM) than in thepreviousexperiment in order to increase
the estrogen-induced signal, as well as the potential
change in signal resulting from SRA knockdown. Both
plasmids showed a substantially elevated luciferase
signal in response to 17β-estradiol treatment (Fig. 6b);
however, knocking down SRA RNA did not attenuate
the estrogen-dependent luciferase expression. On the
contrary, SRA RNA knockdown resulted in a small
(~10–15%) but statistically significant increase in
luciferase expression. This increase is similar to the
percentage increase we described above for PR
mRNA in response to SRA knockdown (Fig. 6a).
In these experiments, we have searched for
evidence for SRA/SRAP modulation of estrogen-de-
pendent transcription of three specific genes and
from specific hormone-dependent promoters when
SRA is depleted from endogenous levels through
siRNA knockdown. The effects we observe range
from negligible to relatively small enhancements of
the level of transcription; they are substantially
smaller and opposite in sign from what would be
expected from previous reports [1,26,31].
Attempts to identify SRA-regulated genes
with RNA-seq
Since we were unable to detect accentuated
regulation of estrogen-responsive gene expression
by SRA/SRAP in the specific cases we examined, we
undertook a genome-wide screen for SRA-regulated
genes by deep sequencing. Although a conceptually
similar experiment using microarrays was described
previously [29], our identification of a siRNA pool that
gave improved knockdown of SRA without affecting
cell growth provided the incentive for new experi-
ments. Cells were grown in normal medium, rather
than hormone-free medium supplemented with
17β-estradiol, in order to more closely approximate
physiological conditions, and were harvested 32 h
after transfection. RT-qPCR (reverse transcription–
quantitative polymerase chain reaction) and Western
blotting confirmed that both SRA and SRAP were
successfully depleted (Fig. 7a). Because SRA RNA
has alternative splicing isoforms, we tested seven
different RT-qPCR primers spanning the entire SRA
core region [1]; all the primers revealed efficient
knockdown.
A total of 157 million reads were generated from
triplicate samples of the pool 2 control siRNA group
(46 million from replicate 1, 62million from replicate 2,
and 49million from replicate 3); 151million readswere
generated from triplicate samples of the pool 2 SRA
siRNA group (57 million from replicate 1, 29 million
from replicate 2, and 65 million from replicate 3). The
reads were aligned to the human genome with the
program tophat version 2.0.4 in conjunction with
bowtie version 2.0.0. Expression level differences of
each genewere analyzed with cuffdiff. Criteria used to
select top candidates for SRA-regulated genes were
as follows: cutoff of q value ≤0.05, fold change ≤0.5 or
≥2, and reads per kilobase per million mapped reads
(RPKM) ≥1. We only identified six genes that met all
the conditions listed above (Table 1 and supplemen-
tary file); as expected, one of these was SRA.
Examination of the distribution of total reads at the
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SRA locus further confirmed the nearly complete
knockdown of this gene product (Fig. 7a, bottom
panel). We then used RT-qPCR to examine the RNA
level of the other five genes (Fig. 7b). Except for
RMRP, the expression level changes of the other four
genes were confirmed and the fold change corre-
sponded well with that obtained from the RNA-seq
results. We then tested whether these genes were
true SRA targets by knocking down SRA with the
individual siRNAs in pool 2 SRA siRNA (Fig. 7c).
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RT-qPCR analysis of SRA RNA level showed that
each of the four siRNAs knocked down SRA
efficiently. However, when we examined the RNA
level of the other five candidate genes, in each case
only one of the four individual siRNAs induced gene
expression changes similar to that induced by the
whole pool. Therefore, the observed gene expression
changes do not correlate rigorously with knockdown of
SRA; they are likely to be off-target effects of individual
siRNAs [32]. We do not observe any changes in gene
expression that can be unequivocally attributed to
depletion of SRA/SRAP.
Discussion
Reevaluation of SRAP as an SRA-binding protein
The contemporarymodel for intertwined activities of
SRAP and SRA states that splice variants of SRA act
asmRNAs to produce SRAP, which in turnmodulates
SRA-dependent transcriptional regulation when its
carboxy-terminal domain binds a specific stem–loop,
STL7, of SRA RNA (Refs. [4,10] and references
therein). We utilized several approaches to evaluate
this model. Working with purified reagents in vitro, we
find that binding of SRA RNA and fragments thereof
by recombinant SRAP has the characteristics of
sequence-nonspecific RNA binding [33]. We found
no binding specificity for STL7 of SRA. To address the
possibility that cellular factors may be required for
assembly of an SRAP–SRA complex, we coex-
pressed SRAP and SRA in HEK293T cells. However,
pull-down of SRAP from cell lysates failed to carry any
significant amount of SRARNA. The carboxy-terminal
domain of SRAP is a five-helix bundle (PDB ID:
2YRU and this work) that has no structural similarity
to known RNA-binding structural domains and in our
hands does not bind RNA. Of the three amino acid
residues whose simultaneous mutation to glycine
was reported to abolish SRA binding [6], the side
chains of two are buried and inaccessible for
interactions. Our results lead us to conclude that the
current model for the function of SRAP needs to be
reevaluated.
We have examined the published accounts of a
specific SRAP–SRA interaction to see how the
discrepancy between previous results and ours
might be resolved. Evidence to support the model
that SRAP specifically binds STL7 of SRA comes
from experiments in which (i) full-length or deletion
mutants of in vitro transcribed RNA were mixed with
RNase-treated, immunoprecipitated endogenous
SRAP from cell lysates, and (ii) the presence of
SRA RNA was monitored by RT-PCR [6]. In these
experiments, of the four SRA deletions tested, only
the deletion of STL7 resulted in a loss of signal
attributed to bound RNA. Our experiments that argue
against SRAP binding specifically to STL7 differ from
these in that we measured protein–RNA binding
directly using purified components.
Experiments have been reported in which SRAP
(endogenous or plasmid expressed) was immunopre-
cipitated from cell lysates, and bound SRA was
monitored by RT-PCR amplification [6]. In view of
the concern that RT-PCR may amplify a minor
component, we utilized Northern blots to test for
stoichiometric levels of binding of SRA to SRAP in
cells, with negative results. Our results still allow the
Table 1. Top candidate SRA-regulated genes in MCF-7 cells identified with RNA-seq.
Gene name RPKMa of control RPKM of SRA knockdown Fold change (SRA knockdown/control) p Value q Value
SRA1 18.8303 1.60853 0.085 0 0
MSRB2 17.6106 2.69954 0.153 0 0
RACGAP1 55.6141 21.8603 0.393 0 0
C3orf58 3.1492 1.53036 0.486 2.75E−07 0.000126
NMD3 137.413 67.1504 0.489 0 0
RMRP 10.5995 26.0199 2.455 3.8E−06 0.00124
a RPKM: reads per kilobase pair per million reads.
Fig. 7. RT-qPCR examination of the top candidates for SRA/SRAP-regulated genes identified with RNA-seq.
(a) Verification of SRA knockdown in the RNA-seq samples. MCF-7 cells were transfected with 25 nM corresponding siRNA
pool. Cells were harvested 32 h after transfection. Top left: SRARNA level, measured by RT-qPCR (error bars represent SD,
n = 3, with GAPDH mRNA as internal control). Top right: SRAP protein level, measured by Western blot (antibody: Abcam
ab72407, with GAPDH protein as internal control). Bottom: RNA-seq data at the locus of SRA also confirm the
knockdown. (b) RT-qPCR verification of the expression level differences of the candidate genes at 32 h after transfection with
25 nM corresponding siRNA pool, with GAPDHmRNA as internal control (error bars represent SD, n = 3). (c) The expression
level changes of the candidate genes are not consistent when SRA is knocked down with individual siRNAs in pool 2. MCF-7
cells were transfected with 25 nM of the indicated siRNA. Thirty-two hours after transfection, RNA levels of SRA and the
candidate genes were examined with RT-qPCR, with GAPDH mRNA as internal control (n = 1).
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possibility that, in the absence of a direct interaction,
SRA and SRAP may co-localize in larger molecular
complexes in some cases.
Function of the SRA system (SRA/SRAP) in
estrogen-dependent transcription in MCF-7 cells
Lack of a specific, stable association of SRAP with
SRA does not rule out the possibility that SRA/SRAP
functions as a transcriptional regulator. To test this, we
have looked for changes in gene expression inMCF-7
cells consequent to siRNA knockdown of SRA, which
depletes both noncoding RNA functions of SRA and
the production of SRAP. First, focusing on specific
estrogen-responsive genes, we found that mRNA
levels increased in response to 17β-estradiol treat-
ment as expected, but the mRNA levels were mostly
insensitive to SRA/SRAP depletion, with the largest
changes being ~15–20%. Then, in a genome-wide
search for SRA/SRAP-dependent genes, we identi-
fied several genes whose expression levels changed
in response to the siRNA knockdown. The genes
identified do not overlap with the set of genes
previously identified as sensitive to SRA siRNA
knockdown by microarray analysis [29]. Further, we
found that in each case we examined, the expression
response was due to a single siRNA of the pool 2
siRNAs, indicating a probable off-target effect. The
largest effects we see in response to SRA/SRAP
depletion are relatively modest, ~15–20%. This
contrasts with the reports of several investigators
[1,26,31] in which overexpression of SRA from
transfected plasmids resulted in as much as a
10-fold enhancement of transcriptional activity. Our
approach differs from theirs in that we looked for
changes of expression in response to SRA/SRAP
depletion from endogenous levels, rather than in
response to overexpression above endogenous levels.
Our concern about overexpression experiments is their
potential to driveweak interactions that would not occur
to any substantial extent at wild-type levels of
macromolecules; thus, transcriptional changes caused
by overexpression of SRA could be real but limited to
the overexpression situation.
We acknowledge that our siRNA knockdown
method does not allow separation-of-function obser-
vationsonSRAPprotein andSRARNA independently.
Previous separation-of-function studies monitoring the
signal from hormone-responsive luciferase reporter
plasmids have given divergent results. In one study
[31], mutagenesis of the SRA sequence in a manner
that would disrupt predictedRNA secondary structures
while leaving the translated protein sequence un-
changed identified several RNA stem–loops whose
putative disruption resulted in attenuation of hormo-
ne-dependent coactivation. A later studyusingasimilar
approach [26] reported enhanced activation at EREs
when RNA secondary structures were disrupted but
translated protein sequence was unchanged. In a
reciprocal experiment in which RNA structure was not
disrupted but protein expression was abolished by
mutagenizing start codons, signals from human
progesterone receptor and pS2 EREs were un-
changed, while the signal from a Xenopus vitellogenin
ERE was enhanced. Hence, a consistent pattern for
separable effects of SRA RNA versus SRAP protein
has not emerged from previous studies. We have not
attempted to separate the effect of SRA depletion
from the effect of SRAP depletion with our knockdown
methodology.
We recognize a number of caveats with our
conclusions, which inevitably are drawn from data
from the selected set of experimental conditions we
haveexplored. In ourRNA-seqexperiments,we looked
for changes occurring at 32 h posttransfection; there is
a possibility of acute responses that are ameliorated by
32 h or effects that occurred on a longer time scale. In
this regard, we have observed time-dependent effects;
for example,weexaminedmRNA levels of pS2andPR
at different times after siRNA transfection and foundPR
up-regulated a few percent on days 2 and 3 (Fig. S6).
However, this effect is relatively subtle. For RNA-seq,
we chose a cutoff for substantial effects on gene
expression of b0.5-fold and N2-fold.We recognize that
genes with more modest responses to SRA knock-
down could be biologically meaningful.
Additionally, previous studies by Klinge et al. have
shown that regulation of ER activity depends on both
the specific sequence of the ERE and the flanking
DNA sequences [14]; we have explored a limited set
of EREsequences. Notably, in the studies byKlinge et
al., it was found that overexpression of SRA had no
significant effect on the estrogen-stimulated transcrip-
tional activity of ERα on pS2 ERE but did inhibit the
activity on PR ERE. This is in agreement with our
results fromSRA knockdown, which showed no effect
on pS2 but a slight enhancement of PR transcriptional
activity when SRA was depleted.
Does PRP18 similarity suggest alternative
functions for SRAP?
If SRAP is not a modulator of SRA-dependent
transcriptional regulation, what is its function? SRAP is
expressed at relatively high levels in cells, and several
independent studies show that it is partitioned in part to
the nucleus (Refs. [8,19,20] and this work). Arguably,
an intriguing hint may come from the structural
similarity of the SRAP carboxy-terminal domain to
that of the yeast PRP18 protein—intriguing because,
although the five-helix bundle is a very simple fold,
these are the only two proteins in the protein structure
database that share it. Unfortunately, the sequence
similarity between these two domains is too low to
allow BLAST searches to “link” them through homol-
ogous sequences, so that tracing a biological function
through a path of sequence relatedness is not an
option.
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PRP18 is involved in the second step of yeast
mRNA splicing. Specifically, genetic and mutagen-
esis studies have demonstrated that the carboxy-
terminal domain interacts with the protein Slu7 at a
weakly conserved face of the domain and with the
protein component of U5 snRNP through the highly
conserved loop region linking helices D and E [34,35].
PRP18 is thought to orient U5 snRNP in amanner that
aligns an RNA loop of U5 snRNP with the exon
junction; PRP18 thereby guides a specific RNA–RNA
interaction through direct protein–protein interactions.
Reasoning by analogy, it is interesting to consider
whether the five-helix bundle found in both SRAP and
PRP18 is a protein domain utilized for specific
protein–protein interactions.
In summary, we do not find convincing evidence that
SRAP interacts with SRA RNA to regulate transcrip-
tion. SRAP resides in part in the nucleus (Refs.
[8,19,20] and this work), suggesting that it is likely to
have a nuclear function. The structural similarity of its
carboxy-terminal domain to that of PRP18 suggests
that it may be involved in the assembly of multisubunit
complexes through specific protein–protein interac-
tions. The (S/T)P-rich central domain suggests that its
activity may be regulated by phosphorylation. Indeed,
proteomic mass spectrometry experiments provide
evidence for phosphorylation by proline-directed
serine, threonine kinases [consensus target se-
quence (S/T)P] in this domain [22–24]. The specific
targets of SRAP, and by implication, its biological
function, remain to be found.
Materials and Methods
Reagents and plasmids
LB-based autoinduction medium with trace metal ions for
E. coli growth was obtained from Formedium, United
Kingdom (AIMLB0210). 17β-Estradiol and fulvestrant
(Sigma) were dissolved in ethanol and dimethyl sulfoxide,
respectively.
SRAP and SLIRP protein-coding sequences that were
codon optimized for expression in E. coli were synthesized
by GenScript and provided in pUC57 plasmids. Standard
cloning methods were used to construct plasmids for
expression of recombinant SRAP and SLIRP or subfrag-
ments thereof in E. coli as either (a) carboxy-terminal
fusions to MBP in tandem with a tobacco etch virus (TEV)
protease cleavage site or (b) amino-terminal fusions to the
intein–chitin binding domain of the pTWIN1 vector (New
England Biolabs). Plasmid pRK1043 for expressing TEV
protease as an MBP-TEV[S219V]-Arg5 protease fusion in
E. coli [36], referred to as MBP-TEV protease in this article,
was obtained from Addgene.
A coding sequence for hSRA (nucleotides 419–1356 of
GenBank sequence NM_001035235) preceded by the T7
promoter and KpnI recognition sequence (used in making
5′ deletions), and with a SapI site at the 3′ end, was
synthesized by GenScript and provided in plasmid pUC57.
The endogenous SapI site of pUC57 was subsequently
removed from the vector.
To construct plasmids for transient transfections in human
cells, the native coding sequence for human SRAP (amino
acid residues 1–236) with an amino-terminal 3×FLAG tag,
and the coding sequence for SRA as described above,
with the two ATG “start” codons for SRAP protein mutated
to TAG “stop” codons, were cloned into vectors provided
by J. Lingner [37] and used for similar coexpression with
hTR and reverse transcriptase protein [25].
pGL3-vitellogenin A2-Luc (which has the vitellogenin A2
promoter region, −331 to −87 [38], inserted upstream of a
minimal TATA box-containing promoter driving firefly lucif-
erase expression) was constructed as follows. Xenopus
laevis genomic DNA was amplified with the sense primer 5′
GGGGTACCGGTCACAGTGACCTG and the antisense
primer 5′AACTGCAGACTGTTATCAGGTTGTGTAAAC.
The amplicon was inserted between the KpnI and PstI
sites of p3APP-Luc, a derivative of pGL3-basic containing
the TATA box sequence: 5′AGGGTATATAAT [39].
pGL3-3 × ERE-Luc (which has three copies of the classic
vitellogenin ERE consensus sequence, TTATAAAGTC
CACGCGCAACCCGCGGACTCACCAT, followed by a
TATA box and the E1a minimal promoter driving firefly
luciferase expression) and pRL-TK (a control plasmid for
luciferase-based assays, which has the thymidine kinase
promoter driving renilla luciferase expression) were contrib-
uted by Dr. Leslie Leinwand, University of Colorado.
Protein expression and purification
Expression plasmids for MBP or intein fusions of SRAP
or SLIRP were transformed into E. coli BL21(DE3) cells,
grown on autoinduction media at 37 °C, and harvested by
centrifugation. Chromatography was done at 4 °C. For
MBP fusions, cells were resuspended in “buffer A” [50 mM
Tris–Cl, 0.1 M NaCl, 0.4 mM ethylenediaminetetraacetic
acid (EDTA), and 1 mM DTT, pH 7.9] and lysed by
sonication. Centrifugation, followed by precipitation of
nucleic acids by addition of polyethyleneimine to a
concentration of 0.1% (w/v) and a second centrifugation,
yielded a lysate that was applied directly to an amylose
affinity column. Protein was eluted with buffer A + 1 M
α-methyl-glucose, concentrated, and purified by fast
protein liquid chromatography gel filtration on a Super-
dex-75 column (GE Healthcare) equilibrated with buffer A.
We found that expression of full-length SRAP in E. coli
consistently yielded, in addition to the full-length product,
shorter variants as a substantial fraction of the product.
Purification and analysis by mass spectrometry of these
variants revealed them to be truncations that terminated
within the central, proline-rich region of SRAP, presumably
as a result of premature translation termination.
Fractions with the desired protein fusion were pooled
and either used as MBP fusions in subsequent experi-
ments (for SLIRP) or cleaved with MBP-TEV protease
overnight at 4 °C. Protease-cleaved fusions were subse-
quently applied to an amylose column (which bound both
the MBP-TEV protease and uncleaved MBP fusion
protein), and the flow-through, which contained protein
without MBP tag, was collected and chromatographed on
Superdex-75 equilibrated with “storage buffer” (20 mM
Mops and 80 mM NaCl, pH 7.0) as a final purification step
and stored frozen.
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Cells with intein fusions were resuspended in “buffer B”
(20 mM Tris–Cl, 0.5 M NaCl, and 0.4 mM EDTA, pH 8.0),
lysed by sonication, centrifuged, and treated with poly-
ethyleneimine as described above for MBP fusions. The
lysate was applied to a chitin column, washed extensively
with buffer B, and then washed with “buffer C” (20 mM
Tris–Cl, 0.1 M NaCl, and 0.4 mM EDTA, pH 8.0); intein
cleavage was effected by equilibrating the column with
buffer C plus 50 mMDTT overnight. Protein was eluted from
the chitin column and chromatographed on Superdex-75
equilibrated with storage buffer and stored frozen.
There are two candidate start codons present in
protein-coding splice variants of SRA RNA [8]. Hence,
both candidate forms of SRAP, starting at Met1 andMet13,
were expressed and purified. With the MBP–SRAP fusions
used, TEV protease cleavage leaves a glycine at the
amino-terminus of the product. The two products are
designated SRAP (1–236) and SRAP (13–236), with the
amino-terminal glycine implied. Additionally, candidate
mRNAs for SRAP identify three isoforms, differing in
translation product by a T50I mutation (SRA2) and a
V110RL insertion/mutation (SRA3) relative to wild type
(SRA1) [8]. However, we have expressed only the wild-type
versions of SRAP. To compare the apparent size of
endogenous SRAP directly with purified protein, we
performed Western blots on endogenous SRAP in HeLa
and HEK293T cell lysates, using recombinant SRAP
proteins as molecular size standards (Fig. S1a). The
endogenous SRAP in HeLa and HEK293T cells aligns
with the shorter form of the protein, SRAP (13–236). MCF-7
cell lysates revealed an endogenous form of SRAP with an
apparent mobility closer to that of SRAP (1–236) (Fig. S1b).
We cloned and sequenced the SRA cDNA fromMCF-7 cells
and found it to be the SRA3 form, with an insertion and
mutation relative to wild-type SRAP. Additionally, the results
of RNA-seq experiments (Fig. S1c) demonstrate the
predominant use of the second start codon, M13, in this
cell line. This is consonant with results of sequencing of 40
clones of SRA isoforms from myogenic cells, which showed
a distribution of transcription start sites in which coding
transcripts favored the second start codon [6]. We conclude
that the second start codon is used predominantly in vivo.
Discrepancies in mobility from recombinant standards or
molecular weight standards on gels, observed by others in
breast cancer cells [8] and HeLa cells [7], as well as by us in
this work, may be due to both the differences in size of the
different isoforms and the posttranslational modification
of SRAP, which has been suggested by several studies
[22–24]. We have not directly addressed the presence or
influence of posttranslational modifications of SRAP in
this work.
MBP-TEV[S219V]-Arg5 protease was expressed and
purified as recommended (Dr. David Waugh‡).
RNA transcription and purification
RNA was transcribed by T7 RNA polymerase from DNA
templates using standard conditions [40]. For STL7 RNA,
a 72-mer consisting of nucleotides 1002–1073 of GenBank
sequence NM_001035235 was transcribed from a
PCR-generated template; 2′-O-methyl deoxyoligonucleo-
tides were incorporated in the two 5′ sites of the 3′ PCR
primer in order to suppress random nucleotide addition
beyond the end of the template by the polymerase [41].
Full-length SRA RNA and large (N200 nucleotides)
fragments thereof were transcribed from plasmids that
had been digested with SapI to define the 3′ terminus.
Since the plasmid used for transcription incorporated a
KpnI site following the T7 promoter, the transcribed RNAs
included a 5′GGUA(CC) in addition to the native SRARNA
sequences, where in some cases one or both of the CC
nucleotides in parentheses were endogenous to SRA.
STL7 RNA was purified by gel filtration on Superdex-75.
Larger fragments of SRA RNAwere purified by gel filtration
on either Superdex-200 or Sephacryl-300.
Electrophoretic mobility shift assays
For use as EMSA substrates, purified RNAs were
dephosphorylated using calf intestinal phosphatase,
purified by phenol extraction and ethanol precipitation,
5′-32P-labeled using T4 polynucleotide kinase, and then
purified on G-25 spin columns. STL7 RNA was heated to
90 °C for 3 min and then snap-cooled on ice; heating and
snap-cooling were avoided with larger RNAs, due to the
potential for misfolding. Trace amounts of RNA (b1 nM)
were equilibrated with protein in a binding buffer consisting
of 20 mM Mops, 80 mM KCl, 0.1 mg/ml bovine serum
albumin, 10 μg/ml polyA, and 5% Ficoll, pH 7.0. Samples
were equilibrated at room temperature for N30 min and then
loaded onto native acrylamide gels and electrophoresed in
TBE at 4 °C. RNA-only samples included xylene cyanol for
tracking; tracking dye was excluded from samples with
protein to avoid the possibility of interference with RNA
binding. After electrophoresis, gels were dried and exposed
on phosphorimager plates by standard methods.
Cell culture
MCF-7 cells were a gift fromDr. Leslie Leinwand. The cells
were routinely grown in complete medium [high-glucose
Dulbecco's modified Eagle's medium (DMEM) with 10% fetal
bovine serum, 2 mM Glutamax-1, 100 U/ml penicillin, and
100 μg/ml streptomycin] at 37 °C, 5% CO2. If cells were
treated with 17β-estradiol, they were grown in hormone-free
medium (high-glucose, phenol-red-free DMEM with 10%
charcoal-stripped fetal bovine serum, 2 mM Glutamax-1,
100 U/ml penicillin, and 100 μg/ml streptomycin) for at least
3 days before the experiment. Plasmids were transfected
into cells with Lipofectamine® 2000 Reagent (Invitrogen)
according to the manufacturer's instructions.
HEK293T cells were grown and transfected with plasmids
as described previously [25].
RNA pull-downs and Northern blots
HEK293T cells were transiently transfected with pairs of
protein andRNAexpression plasmids; cells were grown and
lysates were extracted as described previously [25]. Pull-
down of 3×FLAG-tagged SRAP or hTERT was effected by
agitating lysates with anti-FLAG agarose beads overnight at
4 °C. RNA was extracted from lysates, beads, or superna-
tants from bead pull-downs with TRIzol (Ambion) following
the manufacturer's instructions. Redissolved RNA samples
were run ondenaturing 4%acrylamide gels (7 Murea, TBE);
RNA was transferred to Hybond-N+ membranes (GE
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Healthcare RPN303B) in 1× TBE at 1.0 amp, 1.5 h, and
then crosslinked to the membrane using UV irradiation. A
combination of three different deoxyoligonucleotides hybrid-
izing to different sites of SRA RNA, and two different
oligonucleotides hybridizing to different sites of hTR RNA,
were 5’-32P-labeled and purified as described above.
Hybridization was effected in “RapidHyb’” buffer (GE
Healthcare UK NIF939) at 55 °C for 2 h. Blots were then
washed twicewith 2×SSC + 0.1%SDSand twicewith 0.2×
SSC + 0.1% SDS and exposed to phosphorimager plates.
Western blots
Proteins were heat denatured at 95 °C for 5 min in
sample buffer, separated on polyacrylamide gels
(NuPAGE Bis-Tris, Invitrogen) by SDS–PAGE, and
transferred to HyBond-ECL membranes (GE Healthcare
RPN78D) using standard protocols. The following anti-
bodies were used at specified dilutions: rabbit polyclonal
anti-SRA1 antibody (Abcam, ab72407, 1:5000), rabbit
polyclonal anti-SRA1 antibody (Abcam, ab72552, 1:5000),
and mouse monoclonal GAPDH (A-3) antibody (Santa
Cruz, sc-137179, 1:1000). Secondary antibodies, perox-
idase-AffiniPure donkey anti-rabbit IgG (H + L) (Jackson,
711-035-152, 1:5000) and peroxidase-AffiniPure donkey
anti-mouse IgG (H + L) (Jackson, 715-035-150, 1:5000),
were used to reveal primary antibodies with SuperSignal®
West Pico Chemiluminescent Substrate (Thermo
Scientific). Anti-FLAG antibody (Sigma A8592), used at
1:5000 dilution, is horseradish peroxidase conjugated and
requires no secondary antibody. The signals were
quantified with a FluorChem HD2 imaging system (Alpha
Innotech).
siRNA transfection
Pool 1 SRA siRNA (SRA Smartpool, Dharmacon,
D-120329) has been previously described [29]. Pool 1
non-target siRNA was designed by scrambling the siRNA
sequences in pool 1 SRA siRNA. Sequences of these
siRNAs are listed in Table S1. Pool 2 SRA siRNA is
ON-TARGETplus siRNA pool for human SRA1 (Thermo
Scientific, L-027192-00-0005 and LU-027192-00-0002).
Pool 2 control siRNA is ON-TARGETplus Non-targeting
control pool (Thermo Scientific, D-001810-10-05).
For siRNA transfection, corresponding siRNAs were
reverse transfected into 200,000–300,000 MCF-7 cells with
Lipofectamine® RNAiMAX Reagent (Invitrogen) according to
the manufacturer's instructions.
RT-qPCR
RNA was extracted from cells with TRIzol (Ambion).
cDNA were prepared using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). RT-qPCR
was performed on the LightCycler® 480 Real-Time PCR
System (Roche), with iQ™ SYBR® Green Supermix
(Bio-Rad) or Lightcycler® 480 Probes Master (Roche),
according to specific primers. Sequences of the primers
used are listed in Table S2. The signal of the examined
gene products was normalized to the signal of GAPDH
mRNA for each reaction.
Flow cytometry
MCF-7 cells were trypsinized and separated to single
cells with 70-μm cell strainers. The cell numbers were
measured with the MoFlow flow cytometer (DakoCytomation,
Fort Collins, CO) with a single 488-nm laser. Data were
analyzed using Summit Software (DakoCytomation).
Luciferase assay
Cells were harvested and tested for firefly and renilla
luciferase signals using the Dual-Luciferase® Reporter
Assay System (Promega) according to the manufacturer's
instructions. The signal was examined with the Synergy2
microplate reader (BioTek).
Immunofluorescence
MCF-7 cells were reverse transfected with correspond-
ing siRNAs and seeded on coverslips in 12-well dishes.
Right before harvest, the cells were incubated in DMEM
containing 200 nM MitoTracker® Red CMXRos (Invitro-
gen) for 30 min. Then, the medium was removed and all
the subsequent steps were performed at room tempera-
ture. The cells were fixed with 3.7% formaldehyde in
phosphate-buffered saline for 10 min and permeabilized
with 0.5% Triton-X 100 for 5 min. Then, the cells were
incubated with either Abcam antibody ab72407 (1:200) or
ab72552 (1:100), described above, for 1 h. Cells were then
incubated with Alexa Fluor® 488 goat anti-rabbit (H + L),
highly cross-adsorbed (Invitrogen A11034, 1:500) for
30 min in the dark. Coverslipsweremounted onmicroscope
slides using Vectashield mounting medium with DAPI
(Vector Laboratories), sealed with transparent nail polish,
and stored in the dark at 4 °C until imaging. Images were
obtained using a Nikon A1R confocal microscope and
analyzed with NIS-Elements AR and ImageJ software.
RNA-seq
Total RNAwas purified fromMCF-7 cells treatedwith pool
2 control siRNA or pool 2 SRA siRNA (three replicates for
each group). cDNA libraries were prepared and double-
stranded cDNAwas fragmented using DNase I according to
Illumina specifications, prior to adaptor ligation. Sequencing
libraries were amplified and sequenced using an Illumina
Hiseq 2000 sequencer. RNA-seq reads were aligned to the
human genome (hg19 build) using tophat version 2.0.4,§ in
conjunction with bowtie version 2.0.0.|| Expression level
differences for specific genes were analyzed by cuffdiff.
RNA-seq data have been deposited in the National Center for
Biotechnology Information (NCBI)GeneExpressionOmnibus
data repository.
Protein crystallization and structure determination
A fragment consisting of residues 105–215 of SRAP was
expressed as an intein fusion and purified as described
above. Protein was concentrated to 20 mg/ml, dialyzed into
1.0 Mmalonate(Na+), 0.1 MMops, pH 6.8, and crystallized in
hanging drops by gradually increasing the malonate
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concentration in the precipitant wells from 1.4 M to 2.0 M.
Crystals were stabilized in 2.4 M malonate(Na+) and 0.1 M
Mops, pH 6.5, and flash-frozen in the same solution, which
served as a cryoprotectant.
Crystallographic data were collected on beamline 8.2.2 of
the Advanced Light Source. Native data were collected to
2.8 Å resolution at a wavelength λ = 1.000 Å; a separate
data set was also collected on a second crystal to 4.0 Å
resolution at a wavelength λ = 1.500 Å, using inverse beam
strategy, to measure significant anomalous scattering of
sulfur atoms from cysteine and methionine. Data were
processed with mosflm [42] and HKL2000 [43]. Standard
crystallographic computations were implemented with
CCP4 [44,45] and PHENIX [46]; model building was done
with Coot [47].
The crystals are tetragonal and belong to space group
P43212, with two molecules per asymmetric unit (Table 2).
An initial molecular replacement solution was found using
an unpublished NMR structure of a fragment of mouse
SRAP (PDB ID: 2YRU), which has 85% sequence identity
to the human protein fragment used here, as a search
model. Correct placement of the sequence in themodel was
confirmed with an anomalous difference Fourier using the
data collected at λ = 1.500 Å and model phases; peaks
in the anomalous Fourier align with sulfurs of methio-
nines and cysteines (Fig. S2). Successive cycles of
model building and refinement yielded a model with
Rcryst = 0.224 and Rfree = 0.267; the model includes
residues 109–210 of each protomer; nine residues of
each protomer are disordered in the final model.
PDB and GEO accession codes
Coordinates and structure factors have been deposited
with the Research Collaboratory for Structural Biology with
the identifier 4NBO. RNA-seq data have been deposited in
the NCBI Gene Expression Omnibus data repository,¶
accession identifier GSE52385.
Acknowledgements
We thank Etienne Leygue (University of Manitoba,
Canada) for SRA expression plasmids; Arthur Zaug
(University of Colorado) for performing transfections
and making cell extracts; James Huntley and Steven
Gao (University of Colorado) for performing the
next-generation sequencing; Theresa Nahreini for
assistance with cell culture and sorting; Robin Dowell,
Phillip Richmond, and Mary Allen for help with
RNA-seq data analysis; Rebecca Hoffman for pro-
ducing the Western blots shown in Fig. S1a; and
Leslie Leinwand, Emily Pugach, and members of the
Cech lab for assistance and discussion. T.R.C. is an
investigator of the Howard Hughes Medical Institute.
L.X. is supported by National Institutes of Health grant
T32 GM08759. K.B.B. is supported by AHA
13POST14410014. Crystallographic data were col-
lected at the Berkeley Center for Structural Biology,
which is supported in part by the National Institutes of
Health NIGMS and the Howard Hughes Medical
Institute. Advanced Light Source is supported by the
Director, Office of Science, Office of Basic Energy
Sciences, of the U.S. Department of Energy under
Contract No. DE-AC02-05CH11231.
Appendix A. Supplementary data
Supplementary data to this article can be found
online at http://dx.doi.org/10.1016/j.jmb.2014.01.006.
Received 11 November 2013;
Received in revised form 21 January 2014;
Accepted 22 January 2014
Available online 30 January 2014
Keywords:
estrogen;
nuclear receptor;
RNA-binding protein;
transcription factor;
steroid receptor activator
D.B.M. and L.X. contributed equally to this work.
†www.ebi.ac.uk/dali
‡http://irp.nih.gov/pi/david-waugh
§http://tophat.cbcb.umd.edu
||http://bowtie-bio.sourceforge.net
¶http://www.ncbi.nlm.nih.gov/geo/
Table 2. Crystallographic data collection and refinement
statistics for native data.
Data collection
Wavelength (Å) 1.000
Resolution range (last shell) (Å) 50.0–2.8 (2.85–2.80)
Observations (total/unique) 71,967/9695
Redundancy 7.4 (8.0)
Completeness (%) 99.9 (100.0)
〈I/σ(I)〉a 17.1 (6.3)
Rsym
b 0.059 (0.295)
Refinement
Resolution range (last shell) (Å) 39.5–2.80 (3.21–2.80)
Rcryst
c 0.224 (0.265)
Rfree 0.267 (0.388)
Number of reflections (working set) 9150
Number of reflections (test set) 479
Number of protein atoms 3295
Average B value, all atoms (Å2) 57.4
rmsdd bond length (Å) 0.005
rmsd angles (°) 0.089
Spacegroup P432121, a = 85.90 Å, c = 100.41 Å.
a 〈I/σ(I)〉, intensity divided by standard deviation of intensity,
averaged over all measurements.
b Rsym = ∑|Ihkl − 〈Ihkl〉|/∑〈Ihkl〉, where Ihkl is the single value of
measured intensity of hkl reflection and 〈Ihkl〉 is the mean of all
measured intensity values of hkl reflection.
c Rcryst = ∑|Fobs − Fcalc|/∑Fobs, where Fobs is the observed
structure factor amplitude and Fcalc is the structure factor calculated
from themodel.Rfree is computed in the samemanner asRcryst, using
the test set of reflections.
d rmsd is root-mean-square deviation from ideal value.
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Abbreviations used:
DMEM, Dulbecco's modified Eagle's medium; EDTA,
ethylenediaminetetraacetic acid; EMSA, electrophoretic
mobility shift assay; ER, estrogen receptor; ERE, estrogen-
responsive element; hTERT, human telomerase reverse
transcriptase; hTR, human telomerase RNA; MBP, maltose
binding protein; PDB, Protein Data Bank; PR, progesterone
receptor; GREB1, growth regulation by estrogen in breast
cancer 1; RRM, RNA recognition motif; RT-qPCR, reverse
transcription–quantitative polymerase chain reaction;
SLIRP, SRA stem–loop interacting RNA binding protein;
SRA, steroid receptor RNA activator; SRAP, steroid
receptor RNA activator protein; STL7, stem–loop 7;
TEV, tobacco etch virus.
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